AstraZeneca Reports Phase 3 Results for Savolitinib in MET Exon 14-Mutated NSCLC

AstraZeneca today announced results from the Phase 3 SAFFRON trial evaluating savolitinib in patients with MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC). The trial demonstrated significant improvements in objective response rate and progression-free survival compared to docetaxel in previously treated patients.